Navigation Links
Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
Date:9/25/2010

including Lexiscan, induce arterial vasodilation and hypotension. In postmarketing experience, syncope, transient ischemic attacks, and seizures have been observed. In clinical trials, decreased systolic blood pressure (>35 mm Hg) was observed in 7% of patients and decreased diastolic blood pressure (>25 mm Hg) was observed in 4% of patients within 45 minutes of Lexiscan administration. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency.

Adenosine receptor agonists, including Lexiscan, may result in clinically significant increases in blood pressure in some patients. When it occurred in clinical trials, increased blood pressure was observed within minutes of Lexiscan administration, and in most cases, resolved within 10 to 15 minutes. In some cases, blood pressure increases were observed 45 minutes following Lexiscan administration. In postmarketing experience, cases of potentially clinically significant hypertension have been reported, particularly in patients with underlying hypertension and when low-level exercise was included in the MPI.

Adenosine receptor agonists, including Lexiscan, may cause bronchoconstriction and respiratory compromise. For patients with known or suspected bronchoconstrictive disease, chronic obstructive pulmonary disease (COPD), or asthma, appropriate bronchodilator therapy and resuscitative measures should be available prior to Lexiscan administration.

Lexiscan overdosage may result in serious reactions. Aminophylline was used as a reversal agent in 3% of patients.

The most common adverse reactions (>5%) to Lexiscan are dyspnea, headache, flushing, chest discomfort, angina pectoris or ST-segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia,
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... previously announced underwritten public offering of 7,666,667 shares ... price of $11.25 per share. The shares of ... issued upon the exercise in full by the ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Japan, June 23 Although previous studies,suggest that ... of the eye in children with progressing myopia, ... Using a rigorous study design,and precise optical measuring ... Madrid are undertaking the Myopia Control with,Orthokeratology contact ...
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
Cached Medicine Technology:Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
(Date:7/31/2015)... ... July 31, 2015 , ... ... with the recent implementation of Microsoft Dynamics GP for a senior living facility ... is now supporting senior living communities in 16 states. This further expansion was ...
(Date:7/31/2015)... Nashville, TN (PRWEB) , ... July 31, 2015 ... ... Nashville, Tenn. has launched a Balloon Sinuplasty website to inform potential Nashville ... includes a questionnaire that can be used to determine if someone is a ...
(Date:7/30/2015)... ... July 31, 2015 , ... When responsible for the care of an ... questions race through your mind: What happens if mom falls? Who will remind Dad ... cancel your plans. , But not taking time away from caregiving responsibilities can lead ...
(Date:7/30/2015)... Falls Church, VA (PRWEB) , ... July 31, ... ... Device Manufacturing Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and ... , Dr. Ginette Collazo, a 15 year veteran of helping drug, biologic and ...
(Date:7/30/2015)... ... , ... On July 22nd the Bradenton Herald reported the Opioid ... controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the absence ... crisis in North Florida. The task force has proposed to instate counselors to meet ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3
... at the University of Pennsylvania School of Medicine discovered ... differently when exposed to the tau protein, which plays ... and kinesin proteins transport cellular cargo towards opposite ends ... surface and acts like a speed bump to regulate ...
... N.J., Jan. 17 Following is a,media statement ... of,the New Jersey Hospital Association:, "NJHA applauds ... Patient,Safety Initiative report. This is a valuable document ... report gives us a wealth of information on ...
... JOLLA, Calif., Jan. 17 Immunosyn,Corporation (OTC Bulletin ... a formal "Proof of Concept Trial" for the ... treatment of Diabetic Ulcers., The Board of ... this important,phase of the "Proof of Concept Trial" ...
... in the January 18 edition (Volume 28, Issue 1) of ... of what is known as a nonsense mutation of the ... A nonsense mutation causes the gene to produce proteins that ... of the cytoskeleton, a network of protein fibers or filaments ...
... 2-12 expected this spring, officials add , , THURSDAY, Jan. ... on Thursday issued a public health advisory stating that over-the-counter ... and children under the age of 2. , Although concern ... very young has been widely aired in recent months, FDA ...
... ... children., BERKELEY SPRINGS, W.Va., Jan. 17 The US Food ... too risky,for babies and toddlers on Thursday according to recent reports ... of the serious and,potentially life threatening side effects of cold and ...
Cached Medicine News:Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 2Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 3Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 2Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 3Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 4Health News:FDA to Declare Cold Medicines Too Risky, Homeopathy Offers a Safe Alternative 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: